Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.039734 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von McCall Walker und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology University of Texas Southwestern Medical Center Dallas TX USA. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Lipids, Hypolipidemic Agents, Dyslipidemias. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Peripheral artery disease (PAD), defined by stenosis or occlusion of the extremities (particularly the lower extremities), affects 200 million individuals worldwide, including an estimated 7% of adults in the United States alone. It is the third leading cause of atherosclerotic morbidity after coronary artery disease and stroke. Regardless of symptoms, individuals with PAD are known to be at a significantly increased risk for development of a major adverse cardiovascular event and have a higher all‐cause mortality than those without disease. Despite PAD underdiagnosis, higher atherosclerotic cardiovascular disease burden, and evidence of decreased atherosclerotic cardiovascular disease risk with lipid modification, lipid undertreatment and nontreatment remain common among patients with PAD. This review addresses (1) the role of lipids in the pathophysiology of incident PAD and in adverse outcomes in those with PAD, (2) the role of lipid‐modifying therapies in primary and secondary prevention of PAD, and (3) insights regarding future directions of the study of lipids as it relates to PAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology University of Texas Southwestern Medical Center Dallas TX USA.
- Division of Vascular Medicine University of Texas Southwestern Medical Center Dallas TX USA.
- Division of Cardiovascular Medicine University of Colorado Anschutz Medical Campus Aurora CO USA.
- Advanced Heart and Vein Center Denver CO USA.
ORCID-Profile: Anand Rohatgi, Joshua Beckman, Saket Girotra, Marc P Bonaca, Dharam J Kumbhani
Förderung
- NHLBI NIH HHS
Zitieren
APA
Walker, M., Riggs, K. A., Rohatgi, A., Beckman, J., Addo, T., Girotra, S., Bonaca, M. P., Armstrong, E., & Kumbhani, D. J. (2025). Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039734
Vancouver
Walker M, Riggs KA, Rohatgi A, Beckman J, Addo T, Girotra S, et al. Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039734
BibTeX
@article{Walker2025,
author = {Walker, McCall and Riggs, Kayla A and Rohatgi, Anand and Beckman, Joshua and Addo, Tayo and Girotra, Saket and Bonaca, Marc P and Armstrong, Ehrin and Kumbhani, Dharam J},
title = {Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039734}
}
EUVIMED